The disorder primarily involves degeneration of the peripheral nervous system, which is responsible for transmitting signals between the brain, spinal cord, and muscles. In addition to limb nerves, LPPN3 specifically affects the nerves controlling the larynx (voice box). When these nerves deteriorate, the laryngeal muscles become weak or paralyzed, leading to impaired airway function. At the same time, degeneration in other peripheral nerves causes generalized polyneuropathy affecting mobility and coordination.
Clinical signs of LPPN3 typically appear in young to middle-aged dogs, although onset can vary depending on breed and genetic background. One of the earliest and most noticeable symptoms is noisy breathing (stridor), especially during exercise or excitement. This occurs due to partial or complete paralysis of the larynx, which restricts normal airflow.
As the disease progresses, dogs may develop additional respiratory signs such as exercise intolerance, coughing, gagging, or difficulty breathing in warm environments. In more advanced cases, respiratory distress can become severe and potentially life-threatening, particularly during stress or overheating.
Alongside laryngeal dysfunction, affected dogs also show signs of polyneuropathy, including hind limb weakness, reduced stamina, and unsteady gait (ataxia). Muscle wasting may develop over time due to reduced nerve stimulation. Dogs may have difficulty rising, show decreased reflexes, or exhibit a wide-based stance as coordination worsens. In advanced stages, both respiratory and motor functions may be significantly compromised.
The LPPN3 DNA Health Test is designed to detect the specific genetic mutation responsible for this condition. The test is simple, safe, and non-invasive, typically performed using a cheek swab or blood sample. The DNA is analyzed in a specialized laboratory to determine whether the dog carries zero, one, or two copies of the mutation. Since genetic information does not change throughout life, testing can be performed at any age, including before symptoms appear.
Results are generally reported as:
- Clear (Normal): The dog does not carry the LPPN3 mutation and is not expected to develop or pass on the disease.
- Carrier: The dog carries one copy of the mutation but typically does not show clinical signs. However, it can pass the mutation to offspring.
- Affected/At Risk: The dog carries two copies of the mutation and is expected to develop progressive neurological and respiratory signs associated with LPPN3.
Genetic testing for LPPN3 is highly important for breeders, veterinarians, and dog owners. Breeders can use test results to avoid carrier-to-carrier matings, helping reduce the incidence of this serious combined respiratory and neurological disorder while maintaining healthy genetic diversity.
For dog owners, knowing a dog’s genetic status allows for early monitoring and supportive management. While there is currently no cure for LPPN3, treatment may include respiratory management, activity modification, physiotherapy, and in some cases surgical intervention for laryngeal paralysis to improve breathing. Regular veterinary monitoring is essential to track progression and prevent complications.
The Laryngeal Paralysis and Polyneuropathy (LPPN3) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine neurological and respiratory health, and helps reduce the impact of this inherited multi-system nerve disorder in future generations.
